Daphne Karydas insider trades

Open-market stock purchases and sales by Daphne Karydas, Director at Mineralys Therapeutics, Inc, from SEC Form 4 filings since Dec 10, 2020.

Recent trades

DateStockTradeValue
Sep 15, 2026MLYS Mineralys Therapeutics, IncSold$85.7K
Sep 15, 2026MLYS Mineralys Therapeutics, IncBought (not open market)—
Jun 17, 2026MLYS Mineralys Therapeutics, IncSold$75K
Jun 17, 2026MLYS Mineralys Therapeutics, IncBought (not open market)—
May 27, 2026CMPS COMPASS Pathways plcBought (not open market)—
Mar 31, 2026MLYS Mineralys Therapeutics, IncSold$75K
Mar 31, 2026MLYS Mineralys Therapeutics, IncBought (not open market)—
Feb 19, 2026MLYS Mineralys Therapeutics, IncBought (not open market)—
Feb 19, 2026MLYS Mineralys Therapeutics, IncBought (not open market)—
Nov 13, 2025MLYS Mineralys Therapeutics, IncBought (not open market)—
Nov 13, 2025MLYS Mineralys Therapeutics, IncSold$463K
Nov 13, 2025MLYS Mineralys Therapeutics, IncSold$226K

Companies traded

  • MLYS Mineralys Therapeutics, Inc: 5 sales, last Sep 15, 2026
  • CMPS COMPASS Pathways plc: other filings, last May 27, 2026
  • LOGC LogicBio Therapeutics, Inc: other filings, last Nov 16, 2022
  • SNDX Syndax Pharmaceuticals Inc: other filings, last Feb 3, 2021

Get free alerts when Daphne Karydas files a new trade →